Proton pump inhibitor usage is associated with higher all-cause mortality and CV events in peritoneal dialysis patients

References

• Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2–3.
   PubMed Web of Science ®Google Scholar
• Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–416.
   PubMed Web of Science ®Google Scholar
• Zhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339–347.
   PubMed Web of Science ®Google Scholar
• Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37(7):1237–1241.
   PubMed Web of Science ®Google Scholar
• JLam JR, Schneider JL, Zhao W, et al. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;22:2435–2442.
   Google Scholar
• Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10(6):e124653.
   PubMed Web of Science ®Google Scholar
• Ariel H, Cooke JP. Cardiovascular risk of proton pump inhibitors. Methodist Debakey Cardiovasc J. 2019;15(3):214–219.
   PubMedGoogle Scholar
• Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and Meta-analysis. Nephrol Dial Transplant. 2018;33(2):331–342.
   PubMed Web of Science ®Google Scholar
• Cao H-X, Zhao X-D, Yan L, et al. Correlation between red blood cell distribution width and cardiovascular events in the patients receiving peritoneal dialysis: a Strobe-compliant article. Medicine. 2019;98(6):e14376.
   PubMed Web of Science ®Google Scholar
• Xie Y, Bowe B, Li T, et al. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7(6):e15735.
   PubMed Web of Science ®Google Scholar
• de Francisco ALM, Varas J, Ramos R, et al. Proton pump inhibitor usage and the risk of mortality in hemodialysis patients. Kidney Int Rep. 2018;3(2):374–384.
   PubMed Web of Science ®Google Scholar
• Min YW, Lim KS, Min BH, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther. 2014;40(6):695–704.
   PubMed Web of Science ®Google Scholar
• Chen CB, Lin M, Eurich DT, et al. Safety of concomitant metformin and proton pump inhibitor use: a population retrospective cohort study. Clin Ther. 2016;38(6):1392–1400.
   PubMed Web of Science ®Google Scholar
• Kosedo I, Tokushige A, Takumi T, et al. Use of proton pump inhibitors is associated with an increase in adverse cardiovascular events in patients with hemodialysis: Insight from the kids registry. Eur J Intern Med. 2020;72:79–87.
   PubMed Web of Science ®Google Scholar
• Becker JC, Grosser N, Waltke C, et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun. 2006;345(3):1014–1021.
   PubMed Web of Science ®Google Scholar
• Wu D, Qiu T, Zhang Q, et al. Systematic toxicity mechanism analysis of proton pump inhibitors: an in silico study. Chem Res Toxicol. 2015;28(3):419–430.
   PubMed Web of Science ®Google Scholar
• Yepuri G, Sukhovershin R, Nazari-Shafti TZ, et al. Proton pump inhibitors accelerate endothelial senescence. Circ Res. 2016;118(12):e36–e42.
   PubMed Web of Science ®Google Scholar
• Hoorn EJ, van der Hoek J, de Man RA, et al. Case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010;56(1):112–116.
   PubMed Web of Science ®Google Scholar
• Regolisti G, Cabassi A, Parenti E, et al. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis. 2010;56(1):168–174.
   PubMed Web of Science ®Google Scholar
• Misra PS, Alam A, Lipman ML, et al. The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study. BMC Nephrol. 2015;16(1):136.
   PubMedGoogle Scholar
• Ishimura E, Okuno S, Yamakawa T, et al. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnesium Res. 2007;4:237–244.
   Google Scholar
• Sakaguchi Y, Fujii N, Shoji T, et al. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int. 2014;85(1):174–181.
   PubMed Web of Science ®Google Scholar
• Belin RJ, He K. Magnesium physiology and pathogenic mechanisms that contribute to the development of the metabolic syndrome. Magnesium Res. 2007;20:107–129.
   PubMed Web of Science ®Google Scholar
• Krakauer NY, Krakauer JC. Anthropometrics, metabolic syndrome, and mortality hazard. J Obes. 2018;2018:9241904.
   PubMed Web of Science ®Google Scholar
• Tam M, Gómez S, González-Gross M, et al. Possible roles of magnesium on the immune system. Eur J Clin Nutr. 2003;57(10):1193–1197.
   PubMed Web of Science ®Google Scholar
• Kiadaliri AA, Rosengren BE, Englund M. Fracture-related mortality in Southern Sweden: a multiple cause of death analysis, 1998-2014. Injury. 2018;49(2):236–242.
   PubMed Web of Science ®Google Scholar
• Shih CJ, Chen YT, Ou SM, et al. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol. 2014;177(1):292–297.
   PubMed Web of Science ®Google Scholar
• Casula M, Scotti L, Galimberti F, et al. Use of proton pump inhibitors and risk of ischemic events in the general population. Atherosclerosis. 2018;277:123–129.
   PubMed Web of Science ®Google Scholar
• Ghebremariam YT, Lee JC, LePendu P, et al. Response to letters regarding article, “Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine”. Circulation. 2014;129(13):e428.
   PubMed Web of Science ®Google Scholar
• Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845–853.
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Suzuki H, Minegishi Y, et al. Acid suppression by proton pump inhibitors enhances aquaporin-4 and KCNQ1 expression in gastric fundic parietal cells in mouse. Dig Dis Sci. 2010;55(12):3339–3348.
   PubMed Web of Science ®Google Scholar